KR20190132655A - T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법 - Google Patents

T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법 Download PDF

Info

Publication number
KR20190132655A
KR20190132655A KR1020197030006A KR20197030006A KR20190132655A KR 20190132655 A KR20190132655 A KR 20190132655A KR 1020197030006 A KR1020197030006 A KR 1020197030006A KR 20197030006 A KR20197030006 A KR 20197030006A KR 20190132655 A KR20190132655 A KR 20190132655A
Authority
KR
South Korea
Prior art keywords
leu
ser
val
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197030006A
Other languages
English (en)
Korean (ko)
Inventor
레오니 알텐
도미니크 마우러
세바스티안 붕크
클라우디아 바그너
마티아스 페르버
Original Assignee
이매틱스 바이오테크놀로지스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017106305.6A external-priority patent/DE102017106305A1/de
Application filed by 이매틱스 바이오테크놀로지스 게엠베하 filed Critical 이매틱스 바이오테크놀로지스 게엠베하
Priority to KR1020247033132A priority Critical patent/KR20240151870A/ko
Publication of KR20190132655A publication Critical patent/KR20190132655A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197030006A 2017-03-23 2018-03-23 T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법 Ceased KR20190132655A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247033132A KR20240151870A (ko) 2017-03-23 2018-03-23 T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475329P 2017-03-23 2017-03-23
DE102017106305.6 2017-03-23
DE102017106305.6A DE102017106305A1 (de) 2017-03-23 2017-03-23 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
US62/475,329 2017-03-23
PCT/EP2018/057482 WO2018172533A2 (en) 2017-03-23 2018-03-23 T cell receptors and immune therapy using the same against prame positive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033132A Division KR20240151870A (ko) 2017-03-23 2018-03-23 T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법

Publications (1)

Publication Number Publication Date
KR20190132655A true KR20190132655A (ko) 2019-11-28

Family

ID=61899213

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197030006A Ceased KR20190132655A (ko) 2017-03-23 2018-03-23 T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법
KR1020247033132A Pending KR20240151870A (ko) 2017-03-23 2018-03-23 T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247033132A Pending KR20240151870A (ko) 2017-03-23 2018-03-23 T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법

Country Status (31)

Country Link
US (2) US11236145B2 (https=)
EP (2) EP4450087A3 (https=)
JP (3) JP2020511152A (https=)
KR (2) KR20190132655A (https=)
CN (2) CN110494160B (https=)
AU (2) AU2018240501B2 (https=)
BR (1) BR112019019523A2 (https=)
CA (1) CA3056493A1 (https=)
CL (1) CL2019002645A1 (https=)
CO (1) CO2019011688A2 (https=)
CR (1) CR20190482A (https=)
DK (1) DK3600409T3 (https=)
ES (1) ES2986840T3 (https=)
FI (1) FI3600409T3 (https=)
HR (1) HRP20241228T1 (https=)
HU (1) HUE068640T2 (https=)
IL (2) IL310552B2 (https=)
LT (1) LT3600409T (https=)
MA (1) MA47932B1 (https=)
MD (1) MD3600409T2 (https=)
MX (2) MX2019011260A (https=)
MY (1) MY199084A (https=)
PE (1) PE20191493A1 (https=)
PH (1) PH12019502151A1 (https=)
PL (1) PL3600409T3 (https=)
PT (1) PT3600409T (https=)
RS (1) RS65924B1 (https=)
SG (1) SG11201908023YA (https=)
SI (1) SI3600409T1 (https=)
SM (1) SMT202400351T1 (https=)
TW (1) TWI799922B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
MA55903A (fr) * 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US20220401484A1 (en) * 2019-11-18 2022-12-22 BioNTech SE Prame TCR Receptors And Uses Thereof
EP4093753A1 (en) * 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022017435A1 (zh) * 2020-07-22 2022-01-27 信达生物制药(苏州)有限公司 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230190806A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of treating metastatic lesions and compositions thereof
CN113817044B (zh) * 2021-10-14 2023-10-13 深圳大学总医院 T细胞受体、相关工程化细胞及其应用
CN113789304B (zh) * 2021-10-14 2023-03-31 深圳大学总医院 高亲和力tcr及其应用
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115073584B (zh) * 2022-05-07 2023-10-20 溧阳瑅赛生物医药有限公司 一种特异性识别prame抗原肽的tcr及其应用
CN117946246B (zh) * 2023-02-23 2024-08-06 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
RU2578009C2 (ru) 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
CA2978171A1 (en) 2015-03-10 2016-09-15 J.H. Frederik Falkenburg T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
CN106084036A (zh) 2015-11-02 2016-11-09 广州市香雪制药股份有限公司 识别prame抗原短肽的t细胞受体
CN106478809B (zh) 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr
CN106519019B (zh) 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
CN106699874B (zh) 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
KR102436129B1 (ko) 2016-06-17 2022-08-26 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 및 이의 용도
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) * 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten

Also Published As

Publication number Publication date
CR20190482A (es) 2020-01-07
EP4450087A3 (en) 2025-01-08
SMT202400351T1 (it) 2024-11-15
HUE068640T2 (hu) 2025-01-28
FI3600409T3 (fi) 2024-09-03
CN110494160B (zh) 2024-06-25
PH12019502151A1 (en) 2020-06-29
JP2023088973A (ja) 2023-06-27
JP2020511152A (ja) 2020-04-16
SG11201908023YA (en) 2019-10-30
RS65924B1 (sr) 2024-10-31
IL269578A (en) 2019-11-28
EP3600409A2 (en) 2020-02-05
CN110494160A (zh) 2019-11-22
AU2018240501A1 (en) 2019-10-31
MY199084A (en) 2023-10-12
US11236145B2 (en) 2022-02-01
TWI799922B (zh) 2023-04-21
KR20240151870A (ko) 2024-10-18
IL269578B2 (en) 2024-07-01
MX2023003463A (es) 2023-04-19
ES2986840T3 (es) 2024-11-12
JP7787119B2 (ja) 2025-12-16
CN118852404A (zh) 2024-10-29
DK3600409T3 (da) 2024-09-09
MD3600409T2 (ro) 2024-11-30
IL269578B1 (en) 2024-03-01
TW202208420A (zh) 2022-03-01
IL310552A (en) 2024-03-01
IL310552B2 (en) 2026-04-01
EP3600409B1 (en) 2024-08-14
CA3056493A1 (en) 2018-09-27
HRP20241228T1 (hr) 2024-11-22
AU2018240501B2 (en) 2025-04-10
SI3600409T1 (sl) 2024-10-30
BR112019019523A2 (pt) 2020-04-22
PT3600409T (pt) 2024-09-13
US20220098270A1 (en) 2022-03-31
US20180273602A1 (en) 2018-09-27
MX2019011260A (es) 2019-12-05
PE20191493A1 (es) 2019-10-21
PL3600409T3 (pl) 2024-10-21
LT3600409T (lt) 2024-09-10
IL310552B1 (en) 2025-12-01
MA47932B1 (fr) 2024-09-30
EP4450087A2 (en) 2024-10-23
CO2019011688A2 (es) 2020-02-28
JP2026021299A (ja) 2026-02-10
CL2019002645A1 (es) 2019-12-13
AU2025202086A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7787119B2 (ja) Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法
US11111286B2 (en) T cell receptors and immune therapy using the same against PRAME positive cancers
US20250154246A1 (en) Novel t cell receptors and immune therapy using the same
AU2017373740B2 (en) Novel T cell receptors and immune therapy using the same
WO2018104478A1 (en) Novel t cell receptors and immune therapy using the same
AU2017312361A1 (en) T cell receptors and immune therapy using the same
KR20210109657A (ko) T 세포 수용체 및 이를 사용하는 면역 요법
US20190359677A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
HK40117524A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731B (en) T cell receptors and immune therapy using the same against prame positive cancers
EA043746B1 (ru) Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием
BR122024020723A2 (pt) Construtos reconhecedores de antígenos, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, seus usos contra cânceres positivos para prame e método de fabricação de construto reconhecedor de antígenos associados a tumores

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210322

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230419

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231229

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230419

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20231229

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230818

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210322

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240531

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20240402

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20231229

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230818

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230419

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210322

X601 Decision of rejection after re-examination